Breast cancer in young women: Epidemiology and treatment dilemma;Mammacarcinoom bij jonge vrouwen: Epidemiologie en dilemma's in de behandeling

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 46, 2008, Pages 2495-2500

  Van Der Sangen, M J C ^a   Voogd, A C ^b   Van De Poll Franse, L V ^c   Tjan Heijnen, V C G ^b  

^a CATHARINA HOSPITAL   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c The Netherlands   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CARDIOTOXICITY; FEMALE INFERTILITY; HUMAN; MENOPAUSAL SYNDROME; OSTEOPOROSIS; PRACTICE GUIDELINE; PROGNOSIS; REVIEW; SYSTEMIC THERAPY;

ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FERTILITY; HUMANS; INCIDENCE; PATIENT SATISFACTION; PATIENT SELECTION; PROGNOSIS; QUALITY OF LIFE; RADIOTHERAPY, ADJUVANT; TREATMENT OUTCOME;

EID: 56549110296     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Oldenburg RA, Meijers-Heijboer H, Cornelisse CJ, Devilee P. Genetic susceptibility for breast cancer: how many more genes to be found? Crit Rev Oncol Hematol. 2007;63:125-49.
2. De Sanjosé S, Léoné M, Bérez V, Izquierdo A, Font R, Brunet JM, et al. Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients. Int J Cancer. 2003;106:588-93.
3. Easton DF, Pooley KA, Dunning AM, Pharoah PD, Thompson D, Ballinger DG, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447:1087-93.
4. Xue F, Michels KB. Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence. Lancet Oncol. 2007;8:1088-100.
5. Trichopoulos D. Hypothesis: does breast cancer originate in utero? Lancet. 1990;335:939-40.
6. Michels KB, Terry KL, Willett WC. Longitudinal study on the role of body size in premenopausal breast cancer. Arch Intern Med. 2006; 166:2395-402.
7. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53.297 women with breast cancer and 100.239 women without breast cancer from 54 epidemiological studies. Lancet. 1996; 347:1713-27.
8. Beral V, Bull D, Doll R, Peto R, Reeves G. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83.000 women with breast cancer from 16 countries. Collaborative Group on Hormonal Factors in breast Cancer. Lancet. 2004;363:1007-16.
9. Siesling S, Aa MA van der, Coebergh JW, Pukkala E. Time-space trends in cancer incidence in the Netherlands in 1989-2003. Working Group of the Netherlands Cancer Registry. Int J Cancer. 2008;122: 2106-14.
10. Adami HO, Malker B, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med. 1986;315:559-63.
11. Louwman WJ, Voogd AC, Dijck JA van, Nieuwenhuijzen GA, Ribot J, Pruijt JF, et al. On the rising trends of incidence and prognosis for breast cancer patients diagnosed 1975-2004: a long-term population-based study in southeastern Netherlands. Cancer Causes Control. 2008;19:97-106.
12. Siesling S, Poll-Franse LV van de, Jobsen JJ, Repelaer van Driel OJ, Voogd AC. Explanatory factors for variation in the use of breast conserving surgery and radiotherapy in the Netherlands, 1990-2001. Breast. 2007;16:606-14.
13. Punglia RS, Morrow M, Winer EP, Harris JR. Local therapy and survival in breast cancer. N Engl J Med. 2007;356:2399-405.
14. Early breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687-717.
15. Voogd AC, Nielsen M, Peterse JL, Blichert-Toft M, Bartelink H, Overgaard M, et al. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. Danish Breast Cancer Cooperative Group. Breast Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol. 2001;19:1688-97.
16. Bock GH de, Hage JA van der, Putter H, Bonnema J, Bartelink H, Velde CJ van de. Isolated loco-regional recurrence of breast cancer is more common in young patients and following breast conserving therapy: long-term results of European Organisation for Research and Treatment of Cancer studies. Eur J Cancer. 2006;42:351-6.
17. Elkhuizen PH, Vijver MJ van de, Hermans J, Zonderland HM, Velde CJ van de, Leer JW. Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. Int J Radiat Oncol Biol Phys. 1998;40: 859-67.
18. Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, et al. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? EORTC Radiotherapy, Breast Cancer Groups. Eur J Cancer. 2003;39:932-44.
19. Leest M van der, Evers L, Sangen MJ van der, Poortmans PM, Poll-Franse LV van de, Vulto AJ, et al. The safety of breast-conserving therapy in patients with breast cancer aged < or = 40 years. Cancer. 2007; 109:1957-64.
20. Buchholz TA, Tucker SL, Erwin J, Mathur D, Strom EA, McNeese MD, et al. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol. 2001;19:2240-6.
21. Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol. 2006;24:2437-43.
22. De Laurentiis M, Cancello G, d'Agostino D, Giuliano M, Giordano A, Montagna E, et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol. 2008;26:44-53.
23. Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. LHRH-agonisrs in Early Breast Cancer Overview group. Lancet. 2007;369:1711-23.
24. Thewes B, Meiser B, Taylor A, Phillips KA, Pendlebury S, Capp A, et al. Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol. 2005;23: 5155-65.
25. Boekhout AH, Beijnen JH, Schellens JH. Symptoms and treatment in cancer therapy-induced early menopause. Oncologist. 2006;11: 641-54.
26. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2007;25: 820-8.
27. Del Mastro L, Catzeddu T, Venturini M. Infertility and pregnancy after breast cancer: current knowledge and future perspectives. Cancer Treat Rev. 2006;32:417-22.
28. Recchia F, Saggio G, Amiconi G, di Blasio A, Cesta A, Candeloro G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer. 2006; 106:514-23.
29. Ives A, Saunders C, Bulsara M, Semmens J. Pregnancy after breast cancer: population based study. BMJ. 2007;334:194.
30. Gelber S, Coates AS, Goldhirsch A, Castiglione-Gertsch M, Marini G, Lindtner J, et al. Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol. 2001;19:1671-5.
31. Kroman N, Jensen MB, Melbye M, Wohlfahrt J, Mouridsen HT. Should women be advised against pregnancy after breast-cancer treatment? Lancet. 1997;350:319-22.
32. Ring AE, Smith IE, Jones A, Shannon C, Galani E, Ellis PA. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol. 2005;23:4192-7.